DNA Sequencing and Sorting: Identifying Genetic Variations
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
WARS Recombinant Protein Description Product Info
9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: [email protected] 32-2929: WARS Recombinant Protein Alternative GAMMA-2,IFI53,IFP53,WRS,WARS,TrpRS,hWRS,EC=6.1.1.2,Tryptophanyl-tRNA synthetase,Interferon- Name : induced protein 53,Tryptophan--tRNA ligase,GAMMA-2. Description Source : Escherichia Coli. WARS Recombinant Human produced in E.Coli is a single, non-glycosylated polypeptide chain containing 491 amino acids (1-471 a.a.) and having a molecular mass of 55.3 kDa. The WARS is fused to a 20 amino acid His- Tag at N-terminus and purified by proprietary chromatographic techniques. WARS is part of the class I tRNA synthetase family. 2 types of tryptophanyl tRNA synthetase exist, a cytoplasmic form, called WARS, and a mitochondrial form, called WARS2. WARS catalyzes the aminoacylation of tRNA(trp) with tryptophan and is induced by interferon. WARS controls ERK, Akt, and eNOS activation pathways that are related with angiogenesis, cytoskeletal reorganization and shear stress-responsive gene expression. Product Info Amount : 25 µg Purification : Greater than 90.0% as determined by SDS-PAGE. 1mg/ml solution containing 20mM Tris-HCl pH-8, 1mM DTT, 0.1M NaCl, 1mM DTT & 10% Content : glycerol. Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of Storage condition : time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles. Amino Acid : MGSSHHHHHH SSGLVPRGSH MPNSEPASLL ELFNSIATQG ELVRSLKAGN ASKDEIDSAV KMLVSLKMSY KAAAGEDYKA DCPPGNPAPT SNHGPDATEA EEDFVDPWTV QTSSAKGIDY DKLIVRFGSS KIDKELINRI ERATGQRPHH FLRRGIFFSH RDMNQVLDAY ENKKPFYLYT GRGPSSEAMH VGHLIPFIFT KWLQDVFNVP LVIQMTDDEK YLWKDLTLDQ AYSYAVENAK DIIACGFDIN KTFIFSDLDY MGMSSGFYKN VVKIQKHVTF NQVKGIFGFT DSDCIGKISF PAIQAAPSFS NSFPQIFRDR TDIQCLIPCA IDQDPYFRMT RDVAPRIGYP KPALLHSTFF PALQGAQTKM SASDPNSSIF LTDTAKQIKT KVNKHAFSGG RDTIEEHRQF GGNCDVDVSF MYLTFFLEDD DKLEQIRKDY TSGAMLTGEL KKALIEVLQP LIAEHQARRK EVTDEIVKEF MTPRKLSFDF Q. -
The Structure, Stability and Pheromone Binding of the Male Mouse Protein Sex Pheromone Darcin
The Structure, Stability and Pheromone Binding of the Male Mouse Protein Sex Pheromone Darcin Marie M. Phelan1, Lynn McLean2, Stuart D. Armstrong2, Jane L. Hurst3, Robert J. Beynon2, Lu-Yun Lian1* 1 NMR Centre for Structural Biology, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom, 2 Protein Function Group, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom, 3 Mammalian Behaviour & Evolution Group, Institute of Integrative Biology, University of Liverpool, Leahurst Campus, Neston, United Kingdom Abstract Mouse urine contains highly polymorphic major urinary proteins that have multiple functions in scent communication through their abilities to bind, transport and release hydrophobic volatile pheromones. The mouse genome encodes for about 20 of these proteins and are classified, based on amino acid sequence similarity and tissue expression patterns, as either central or peripheral major urinary proteins. Darcin is a male specific peripheral major urinary protein and is distinctive in its role in inherent female attraction. A comparison of the structure and biophysical properties of darcin with MUP11, which belongs to the central class, highlights similarity in the overall structure between the two proteins. The thermodynamic stability, however, differs between the two proteins, with darcin being much more stable. Furthermore, the affinity of a small pheromone mimetic is higher for darcin, although darcin is more discriminatory, being unable to bind bulkier ligands. These attributes are due to the hydrophobic ligand binding cavity of darcin being smaller, caused by the presence of larger amino acid side chains. Thus, the physical and chemical characteristics of the binding cavity, together with its extreme stability, are consistent with darcin being able to exert its function after release into the environment. -
The Bio Revolution: Innovations Transforming and Our Societies, Economies, Lives
The Bio Revolution: Innovations transforming economies, societies, and our lives economies, societies, our and transforming Innovations Revolution: Bio The Executive summary The Bio Revolution Innovations transforming economies, societies, and our lives May 2020 McKinsey Global Institute Since its founding in 1990, the McKinsey Global Institute (MGI) has sought to develop a deeper understanding of the evolving global economy. As the business and economics research arm of McKinsey & Company, MGI aims to help leaders in the commercial, public, and social sectors understand trends and forces shaping the global economy. MGI research combines the disciplines of economics and management, employing the analytical tools of economics with the insights of business leaders. Our “micro-to-macro” methodology examines microeconomic industry trends to better understand the broad macroeconomic forces affecting business strategy and public policy. MGI’s in-depth reports have covered more than 20 countries and 30 industries. Current research focuses on six themes: productivity and growth, natural resources, labor markets, the evolution of global financial markets, the economic impact of technology and innovation, and urbanization. Recent reports have assessed the digital economy, the impact of AI and automation on employment, physical climate risk, income inequal ity, the productivity puzzle, the economic benefits of tackling gender inequality, a new era of global competition, Chinese innovation, and digital and financial globalization. MGI is led by three McKinsey & Company senior partners: co-chairs James Manyika and Sven Smit, and director Jonathan Woetzel. Michael Chui, Susan Lund, Anu Madgavkar, Jan Mischke, Sree Ramaswamy, Jaana Remes, Jeongmin Seong, and Tilman Tacke are MGI partners, and Mekala Krishnan is an MGI senior fellow. -
[One Step]WARS Antibody Kit
Leader in Biomolecular Solutions for Life Science [One Step]WARS Antibody Kit Catalog No.: RK05722 Basic Information Background Catalog No. Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate RK05722 amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first Applications proteins that appeared in evolution. Two forms of tryptophanyl-tRNA synthetase exist, a WB cytoplasmic form, named WARS, and a mitochondrial form, named WARS2. Tryptophanyl-tRNA synthetase (WARS) catalyzes the aminoacylation of tRNA(trp) with Cross-Reactivity tryptophan and is induced by interferon. Tryptophanyl-tRNA synthetase belongs to the Human, Mouse, Rat class I tRNA synthetase family. Four transcript variants encoding two different isoforms have been found for this gene. Observed MW 53-55kDa Calculated MW 48kDa/53kDa Category Antibody kit Product Information Component & Recommended Dilutions Source Catalog No. Product Name Dilutions Rabbit RK05722-1 WARS Rabbit pAb 1:1000 dilution Purification RK05722-2 HRP Goat Anti-Rabbit IgG (H+L) 1:10000 dilution Affinity purification Storage Store at -20℃. Avoid freeze / thaw Immunogen Information cycles. Buffer: PBS with 0.02% sodium azide, Gene ID Swiss Prot 50% glycerol, pH7.3. 7453 P23381 Avoid repeated freeze-thaw cycles. Immunogen Recombinant fusion protein containing a sequence corresponding to amino acids 1-270 Contact of human WARS (NP_776049.1). www.abclonal.com Synonyms WARS;GAMMA-2;IFI53;IFP53 Validation Data Western blot analysis of extracts of various cells, using WARS antibody (A5758) at 1:1000 dilution ratio through one-step method. Antibody | Protein | ELISA Kits | Enzyme | NGS | Service For research use only. -
Genomic Sequencing of Infectious Pathogens
Science, Technology Assessment, MARCH 2021 and Analytics WHY THIS MATTERS Genomic sequencing reveals the genetic code of an infectious disease pathogen, such as SARS-CoV-2, the SCIENCE & TECH SPOTLIGHT: virus that causes COVID-19. Newer, faster, and less costly sequencing can now be used to more quickly track GENOMIC SEQUENCING OF transmission, detect new variants, and develop vaccines and other countermeasures. However, challenges such INFECTIOUS PATHOGENS as high startup costs and privacy concerns remain. /// THE TECHNOLOGY How mature is it? First-generation sequencing is often used to confirm results of NGS. NGS is relatively new to the public health field, but is used What is it? Genomic sequencing technologies decode a pathogen’s to augment surveillance (i.e., data collection and analysis) for SARS- genetic material by identifying the order of chemical “letters” of its DNA CoV-2 in the U.S. and overseas. New technologies are allowing greater (or RNA, its chemical equivalent in some viruses). Each of four letters access to sequencing capabilities by making NGS portable, faster, and represents a chemical unit called a base. The sequence of the bases can more affordable (the cost of one sequence run is now one-millionth of reveal useful information for combatting disease. For example, sequencing what it was two decades ago). Genomic sequencing technologies enable of SARS-CoV-2 is used to track the spread of various strains, known as many different areas of infectious disease study. For example, they enable variants (see fig. 1). genomic epidemiology—the science of using pathogen genomic data to determine the distribution and spread of an infectious disease in a group How does it work? Technologies for sequencing genomes of pathogens of people or animals, and the application of this information to respond to use chemicals to break up the DNA or RNA into small fragments. -
Tryptophanyl Trna Synthetase (WARS) (NM 004184) Human Tagged ORF Clone Product Data
OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC203587L4 Tryptophanyl tRNA synthetase (WARS) (NM_004184) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: Tryptophanyl tRNA synthetase (WARS) (NM_004184) Human Tagged ORF Clone Tag: mGFP Symbol: WARS1 Synonyms: GAMMA-2; HMN9; IFI53; IFP53; WARS Vector: pLenti-C-mGFP-P2A-Puro (PS100093) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC203587). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_004184 ORF Size: 1413 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Tryptophanyl tRNA synthetase (WARS) (NM_004184) Human Tagged ORF Clone – RC203587L4 OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_004184.3 RefSeq Size: 2884 bp RefSeq ORF: 1416 bp Locus ID: 7453 UniProt ID: P23381, A0A024R6K8 Domains: WHEP-TRS, tRNA-synt_1b Protein Families: Druggable Genome Protein Pathways: Aminoacyl-tRNA biosynthesis, Tryptophan metabolism MW: 53.2 kDa Gene Summary: Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. -
The Genomics Era: the Future of Genetics in Medicine - Glossary
The Genomics Era: the Future of Genetics in Medicine - Glossary The glossary below provides a list of key terms used throughout the course. You do not need to read them all now; we’ll be linking back to the main glossary step wherever these terms appear, so you may refer back to this list if you are unsure of the terminology being used. Term Definition The process of matching reads back to their original Alignment position in the reference genome. An allele is one of a number of alternative forms of the same gene or genetic locus. We inherit one copy Allele of our genetic code from our mother and one copy of our genetic code from our father. Each copy is known as an allele. Microarray based genomic comparative hybridisation. This is a technique used to detect chromosome imbalances by comparing patient and control DNA and comparing differences between the two sets. It is Array CGH a useful technique for detecting small chromosome deletions and duplications which would not have been detected with more traditional karyotyping techniques. A unit of DNA. There are four bases which form the Base cross links (or rungs) of the DNA double helix: adenine (A), thymine (T), guanine (G) and cytosine (C). Capture see Target enrichment. The process by which a cell becomes specialized in Cell differentiation order to perform a specific function. Centromere The point at which the sister chromatids are joined. #1 FutureLearn A structure located in the nucleus all living cells, comprised of DNA bound around proteins called histones. The normal number of chromosomes in each Chromosome human cell nucleus is 46 and is composed of 22 pairs of autosomes and a pair of sex chromosomes which determine gender: males have an X and a Y chromosome whilst females have two X chromosomes. -
DNA Sequencing) Time Binding Sites and Other Functional Sites Using Sequencing As a Means of Evaluating Chromatin Immunoprecipitation (Chip) Elaine R
COMMENTARY for re-sequencing genomes. With next- generation-based applications, we rapidly A brief history of will begin to annotate the human genome with the positions of regulatory protein- (DNA sequencing) time binding sites and other functional sites using sequencing as a means of evaluating chromatin immunoprecipitation (ChIP) Elaine R. Mardis experiments. A variant of ChIP will eluci- date how genome-wide patterns of histone Each spring, I co-teach a course to under- binding and DNA methylation relate to graduates that aims to introduce them to gene-expression regulation in various cell the brief history of genome sequencing states, such as differentiation or disease. and then immerses them in its current The short read-lengths of next-generation practices. Looking out at their eager faces, platforms also are ideal for discovering the I try (perhaps in vain) to capture for them sequences of non-coding RNA genes that in a 1 hour lecture what has been my life’s cannot be elucidated by in silico methods. focus for the past 20 years or so — DNA Bioinformatics-based analysis of genome- sequencing. If forced to summarize this wide DNA copy number, DNA-sequence time period succinctly, I would say, “Never variation and RNA-expression data sets, all a dull moment!” This is largely owing to the produced by next-generation sequencers, technological advances that have catapulted will be integrated to stitch together the genome sequencing from a cottage industry pieces of the biological ‘story’ being told to a high-throughput enterprise, akin to by genomic data. These stories will, in a factory. -
Precise Genetic Mapping and Integrative Bioinformatics in Diversity Outbred Mice Reveals Hydin As a Novel Pain Gene
Mamm Genome (2014) 25:211–222 DOI 10.1007/s00335-014-9508-0 Precise genetic mapping and integrative bioinformatics in Diversity Outbred mice reveals Hydin as a novel pain gene Jill M. Recla • Raymond F. Robledo • Daniel M. Gatti • Carol J. Bult • Gary A. Churchill • Elissa J. Chesler Received: 14 January 2014 / Accepted: 5 March 2014 / Published online: 5 April 2014 Ó The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Mouse genetics is a powerful approach for interaction. Our results reveal a novel, putative role for the discovering genes and other genome features influencing protein-coding gene, Hydin, in thermal pain response, human pain sensitivity. Genetic mapping studies have possibly through the gene’s role in ciliary motility in the historically been limited by low mapping resolution of choroid plexus–cerebrospinal fluid system of the brain. conventional mouse crosses, resulting in pain-related Real-time quantitative-PCR analysis showed no expression quantitative trait loci (QTL) spanning several megabases differences in Hydin transcript levels between pain-sensi- and containing hundreds of candidate genes. The recently tive and pain-resistant mice, suggesting that Hydin may developed Diversity Outbred (DO) population is derived influence hot-plate behavior through other biological from the same eight inbred founder strains as the Collab- mechanisms. orative Cross, including three wild-derived strains. DO mice offer increased genetic heterozygosity and allelic diversity compared to crosses involving standard mouse Introduction strains. The high rate of recombinatorial precision afforded by DO mice makes them an ideal resource for high-reso- Human pain sensitivity varies widely between individuals, lution genetic mapping, allowing the circumvention of and the significant influence of genetic factors on pain costly fine-mapping studies. -
Cloning, DNA Amplification.Pdf
Molecular Biology DNA structure and function Recombinant DNA technology DNA amplification DNA sequencing Arthur Günzl, PhD Dept. of Genetics & Genome Sciences University of Connecticut Health Center Bioinformatics and Computational Biology Course (BME5800) September 13, 2016 Deoxyribonucleic Acid (DNA) 5’ 3’ 2’ The haploid human genome consists of ~3,000,000,000 bp The combined a-helical length is ~2 m A human nucleus’ diameter is ~10 mm, containing 46 chromosomes From Alberts et al., Molecular Biology of the Cell Which one is the reverse primer ? 5’-TTGGGAAGCTCCTTGTCA-3’ |||||||||||||||||| 3’-AACCCTTCGAGGAACAGT-5’ a. 5’-ACTGTTCCTCGAAGGGTT-3’ b. 5’-AACCCTTCGAGGAACAGT-3’ c. 5’-TGACAAGGAGCTTCCCAA-3’ d. 5’-GGTCCTGGAGAAAAGTCT-3’ e. None of the above Recombinant DNA Technology Recombination Process in which DNA molecules are broken and the fragments are rejoined in new combinations Recombinant DNA Any DNA molecule formed by joining DNA segments from different sources Recombinant DNA Technology Key Enzymes Restriction enzyme One of a large number of endonucleases that can cleave a DNA molecule at any site where a specific short nucleo- tide sequence occurs 5’-...GTACCTAGAATTCTT CTAG...-3’ ||||||||||||||||| 3’-...CATGGATCTTAAGTT GATC...-5’ Eco RI (sticky end) 5’-...GTACCTAG AATTCCTAGTG...-3’ |||||||| ||||||| 3’-...CATGGATCTTAA GGATCAC...-5’ SmaI CCC GGG Serratia marcescens Recombinant DNA Technology Key Enzymes DNA ligase Enzyme that joins the ends of two DNA strands together with a covalent bond to make a continuous DNA strand 5’-...GTACCTACCC-3’ 5’-pGGGCTAGTG...-3’ |||||||||| ||||||||| 3’-...CATGGATGGGp-5’ 3’-CCCGATCAC...-5’ T4 DNA ligase + ATP 5’-...GTACCTACCCGGGCTAGTG...-3’ ||||||||||||||||||| 3’-...CATGGATGGGCCCGATCAC...-5’ Recombinant DNA Technology plasmid cloning vector Multiple Cloning Site Gene cloning gene plasmid donor DNA vector RESTRICTION DIGEST DNA LIGASE (ATP) recombinant plasmid Transformation of E. -
Bioinformatics: a Practical Guide to the Analysis of Genes and Proteins, Second Edition Andreas D
BIOINFORMATICS A Practical Guide to the Analysis of Genes and Proteins SECOND EDITION Andreas D. Baxevanis Genome Technology Branch National Human Genome Research Institute National Institutes of Health Bethesda, Maryland USA B. F. Francis Ouellette Centre for Molecular Medicine and Therapeutics Children’s and Women’s Health Centre of British Columbia University of British Columbia Vancouver, British Columbia Canada A JOHN WILEY & SONS, INC., PUBLICATION New York • Chichester • Weinheim • Brisbane • Singapore • Toronto BIOINFORMATICS SECOND EDITION METHODS OF BIOCHEMICAL ANALYSIS Volume 43 BIOINFORMATICS A Practical Guide to the Analysis of Genes and Proteins SECOND EDITION Andreas D. Baxevanis Genome Technology Branch National Human Genome Research Institute National Institutes of Health Bethesda, Maryland USA B. F. Francis Ouellette Centre for Molecular Medicine and Therapeutics Children’s and Women’s Health Centre of British Columbia University of British Columbia Vancouver, British Columbia Canada A JOHN WILEY & SONS, INC., PUBLICATION New York • Chichester • Weinheim • Brisbane • Singapore • Toronto Designations used by companies to distinguish their products are often claimed as trademarks. In all instances where John Wiley & Sons, Inc., is aware of a claim, the product names appear in initial capital or ALL CAPITAL LETTERS. Readers, however, should contact the appropriate companies for more complete information regarding trademarks and registration. Copyright ᭧ 2001 by John Wiley & Sons, Inc. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic or mechanical, including uploading, downloading, printing, decompiling, recording or otherwise, except as permitted under Sections 107 or 108 of the 1976 United States Copyright Act, without the prior written permission of the Publisher. -
Guide to Interpreting Genomic Reports: a Genomics Toolkit
Guide to Interpreting Genomic Reports: A Genomics Toolkit A guide to genomic test results for non-genetics providers Created by the Practitioner Education Working Group of the Clinical Sequencing Exploratory Research (CSER) Consortium Genomic Report Toolkit Authors Kelly East, MS, CGC, Wendy Chung MD, PhD, Kate Foreman, MS, CGC, Mari Gilmore, MS, CGC, Michele Gornick, PhD, Lucia Hindorff, PhD, Tia Kauffman, MPH, Donna Messersmith , PhD, Cindy Prows, MSN, APRN, CNS, Elena Stoffel, MD, Joon-Ho Yu, MPh, PhD and Sharon Plon, MD, PhD About this resource This resource was created by a team of genomic testing experts. It is designed to help non-geneticist healthcare providers to understand genomic medicine and genome sequencing. The CSER Consortium1 is an NIH-funded group exploring genomic testing in clinical settings. Acknowledgements This work was conducted as part of the Clinical Sequencing Exploratory Research (CSER) Consortium, grants U01 HG006485, U01 HG006485, U01 HG006546, U01 HG006492, UM1 HG007301, UM1 HG007292, UM1 HG006508, U01 HG006487, U01 HG006507, R01 HG006618, and U01 HG007307. Special thanks to Alexandria Wyatt and Hugo O’Campo for graphic design and layout, Jill Pope for technical editing, and the entire CSER Practitioner Education Working Group for their time, energy, and support in developing this resource. Contents 1 Introduction and Overview ................................................................ 3 2 Diagnostic Results Related to Patient Symptoms: Pathogenic and Likely Pathogenic Variants . 8 3 Uncertain Results